To evaluate the combined effect of SALM3 on the prognosis of GC, we classified patients into four subgroups according to the SALM3 expression in tumor cells and fibroblasts: group I had low expression of the two distributions, group II had low tumor cell and high fibroblast expression, group III had high tumor cell and low fibroblast expression, and group IV had a high expression of both distributions. The gene discussed is LRFN4; the disease is neoplasm.